- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/555 - Interférons [IFN]
Détention brevets de la classe C07K 14/555
Brevets de cette classe: 308
Historique des publications depuis 10 ans
|
23
|
22
|
22
|
27
|
19
|
22
|
25
|
28
|
13
|
13
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Opko Biologics Ltd. | 79 |
13 |
| The Regents of the University of California | 20815 |
10 |
| Orionis Biosciences Inc. | 111 |
8 |
| Werewolf Therapeutics, Inc. | 66 |
8 |
| Superlab Far East Limited | 15 |
7 |
| Toray Industries, Inc. | 7139 |
6 |
| Regeneron Pharmaceuticals, Inc. | 4786 |
6 |
| Evotec International GmbH | 89 |
5 |
| The Industry & Academic Cooperation in Chungnam National University (IAC) | 518 |
5 |
| Novagen Holding Corporation | 19 |
5 |
| Rutgers, The State University of New Jersey | 1981 |
5 |
| Universiteit Gent | 1411 |
5 |
| Vib VZW | 912 |
5 |
| Sanofi | 4319 |
5 |
| CytomX Therapeutics, Inc. | 233 |
4 |
| Orionis Biosciences BV | 81 |
4 |
| The Board of Trustees of the Leland Stanford Junior University | 6687 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
3 |
| Memed Diagnostics Ltd. | 80 |
3 |
| PharmaEssentia Corp. | 80 |
3 |
| Autres propriétaires | 195 |